Ademetionine

Ademetionine

SCHEMBL1980697

C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O.S

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 5/20 0.98
AMD1 P17707 4/20 0.98
PCMT1 P22061 3/20 0.85
PRMT5 O14744 3/20 0.85
PRMT1 Q99873 3/20 0.85
NSD3 Q9BZ95 2/20 0.85
PRMT3 O60678 2/20 0.85
PNMT P11086 2/20 0.85
PRMT6 Q96LA8 2/20 0.85
WDR77 Q9BQA1 2/20 0.85
PRMT7 Q9NVM4 2/20 0.85
ADORA3 P0DMS8 1/20 0.85
KDR P35968 1/20 0.85
PRMT8 Q9NR22 1/20 0.85
NNMT P40261 3/20 0.71
DOT1L Q8TEK3 5/20 0.70
NSD2 O96028 3/20 0.70
SETD7 Q8WTS6 3/20 0.70
EHMT2 Q96KQ7 3/20 0.70
TRDMT1 O14717 2/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ademetionine SCHEMBL2007787 0.99 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1
Ademetionine SCHEMBL7810282 0.99 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1
Ademetionine SCHEMBL3202538 0.99 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1
Ademetionine SCHEMBL4164615 0.99 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1
Ademetionine SCHEMBL599664 0.99 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1
Ademetionine SCHEMBL600368 0.99 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1
Ademetionine SCHEMBL66767 0.99 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1
Ademetionine SCHEMBL59293 0.99 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1
Ademetionine SCHEMBL55479 0.99 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1
Ademetionine SCHEMBL13033865 0.99 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110150820-A1 METHODS FOR COVALENTLY ATTACHING A POLYMER TO A METHIONINE RESIDUE IN PROTEINS AND PEPTIDES INSIGHT BIOPHARMACEUTICALS LTD. (IL) 2011-06-23 US disclosed
WO-2010023670-A2 METHODS FOR COVALENTLY ATTACHING A POLYMER TO A METHIONINE RESIDUE IN PROTEINS AND PEPTIDES INSIGHT BIOPHARMACEUTICALS LTD. (IL) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110150820-A1 METHODS FOR COVALENTLY ATTACHING A POLYMER TO A METHIONINE RESIDUE IN PROTEINS AND PEPTIDES LNPEP, MGMT, DNPEP CARM1 1627/4885AMD1 82/4885PCMT1 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.